Twin Lakes Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Twin Lakes Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$32.4K	Hold	682	–	–	0.01%	154
2025 Q4	$35.8K	Hold	682	–	–	0.02%	151
2025 Q3	$44.2K	Hold	682	–	–	0.02%	139
2025 Q2	$33.2K	Hold	682	–	–	0.02%	148
2025 Q1	$23.2K	Hold	682	–	–	0.02%	163
2024 Q4	$26.8K	Hold	682	–	–	0.02%	168
2024 Q3	$32K	Hold	682	–	–	0.02%	160
2024 Q2	$36.8K	Hold	682	–	–	0.03%	153
2024 Q1	$46.5K	Hold	682	–	–	0.03%	146
2023 Q4	$42.7K	Hold	682	–	–	0.03%	145
2023 Q3	$31K	Hold	682	–	–	0.02%	153
2023 Q2	$38.3K	Sell	682 -90	-12%	-$5.11K	0.03%	146
2023 Q1	$34.9K	Hold	772	–	–	0.03%	148
2022 Q4	$31.4K	Hold	772	–	–	0.02%	152
2022 Q3	$50K	Buy	+772	New	+$55.9K	0.04%	135
2022 Q2	–	Sell	-772	Closed	-$48K	–	175
2022 Q1	$48K	Buy	772 +344	+80%	+$21.6K	0.03%	159
2021 Q4	$32K	Hold	428	–	–	0.02%	175
2021 Q3	$48K	Hold	428	–	–	0.03%	155
2021 Q2	$69K	Hold	428	–	–	0.04%	119
2021 Q1	$52K	Buy	+428	New	+$64.6K	0.03%	128

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GSK plc London $599M AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Twin Lakes Capital Management's CRSP Position: Q1 2026 in Review

Twin Lakes Capital Management held its CRISPR Therapeutics (CRSP) position steady in Q1 2026 at 682 shares worth $32.4K. The position accounts for 0.01% of the portfolio, ranked #154.

Twin Lakes Capital Management first reported a position in CRSP in Q1 2021 and has held it in 20 quarters since. The position peaked at $69K in Q2 2021. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

Twin Lakes Capital Management held 682 shares of CRISPR Therapeutics worth $32.4K as of Q1 2026.
Twin Lakes Capital Management left its CRISPR Therapeutics share count unchanged in Q1 2026.
CRISPR Therapeutics made up 0.01% of Twin Lakes Capital Management's portfolio in Q1 2026, its #154 holding.
Twin Lakes Capital Management first reported a position in CRISPR Therapeutics in Q1 2021 and has held it in 20 quarters since.
Twin Lakes Capital Management's CRISPR Therapeutics position peaked at $69K in Q2 2021.
488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Twin Lakes Capital Management's 13F filing for Q1 2026, filed 18 May 2026.